All In Biotech

NDA 211913 · Sun Pharm

Absorica Ld

Isotretinoin · Oral · Retinoid

Last checked: Nov 20, 2026Latest source record: Oct 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Nov 5, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

179

33 Phase 3, 11 recruiting

FAERS reports

16,326

8,845 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY – CONTRAINDICATED IN PREGNANCY ABSORICA/ABSORICA LD can cause life-threatening birth defects and is contraindicated in pregnancy. There is an extremely high risk that life-threatening birth defects will result if pregnancy occurs while taking any amount of ABSORICA/ABSORICA LD even for short periods of time. Potentially any fetus exposed during pregnancy can be affected. There are no accurate means of determining prenatally whether an exposed fetus has been affected. If pregnancy occurs, discontinue ABSORICA/ABSORICA LD immediately and refer the patient to an Obstetrician- Gynecologist experienced in reproductive toxicity for further evaluation and counseling [see Contraindications (4) , Warnings and Precautions (5.1) , and Use in Specific Populations (8.1) ]. Because of the risk of embryo-fetal toxicity, ABSORICA and ABSORICA LD are available only through...

What it is approved for

From the label in effect Aug 19, 2026.

ABSORICA and ABSORICA LD are indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. Limitations of Use If a second course of ABSORICA/ABSORICA LD treatment is needed, it is not recommended before a 2-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment [see Dosage and Administration (2.2) ]. ABSORICA and ABSORICA LD are retinoids indicated for the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater. Because of significant adverse reactions associated with its use, ABSORICA and ABSORICA LD are reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. (1) Limitations of Use: If a second course of ABSORICA/ABSORICA LD treatment is needed, it is not recommended before a two-month waiting period because the patient’s acne may continue to improve following a 15 to 20-week course of treatment. (1)

Mechanism: The exact mechanism of action of ABSORICA/ABSORICA LD in the treatment of severe recalcitrant nodular acne in non-pregnant patients 12 years of age and older with multiple inflammatory nodules with a diameter of 5 mm or greater who are unresponsive to conventional therapy, including systemic antibiotics is unknown. ABSORICA/ABSORICA LD is a retinoid, which inhibits sebaceous gland function and keratinization. Clinical improvement in nodular acne patients occurs in association with a reduction in sebum secretion. The decrease in sebum secretion is temporary and reflects a reduction in...

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 5, 2019 Original approval · New Combination and New Formulation or New Manufacturer LabelLetterReview
6 products under this application
  • ABSORICA LD · ISOTRETINOIN 28MG · CAPSULE, ORAL · Discontinued
  • ABSORICA LD · ISOTRETINOIN 20MG · CAPSULE, ORAL · Discontinued
  • ABSORICA LD · ISOTRETINOIN 8MG · CAPSULE, ORAL · Prescription
  • ABSORICA LD · ISOTRETINOIN 32MG · CAPSULE, ORAL · Prescription
  • ABSORICA LD · ISOTRETINOIN 24MG · CAPSULE, ORAL · Prescription
  • ABSORICA LD · ISOTRETINOIN 16MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Isotretinoin" as an intervention, any sponsor and status, largest first.

All 179 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • depression1,058
  • pregnancy1,040
  • exposure during pregnancy775
  • abortion induced728
  • adverse drug reaction670
  • product dose omission issue626
  • headache578
  • dry skin577
  • arthralgia563
  • suicidal ideation535
  • drug ineffective521
  • mood altered467

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004124
2005209
2006355
2007491
2008766
2009503
2010492
2011276
2012383
2013260
2014158
2015197
2016229
2017245
2018389
2019394
2020691
20211,033
20221,547
20231,709
20242,199
20252,321
20261,355

Recalls

2 FDA enforcement reports for this application.

  • Dec 7, 2018 · Class III · Terminated

    Subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring.

  • Jun 26, 2015 · Class II · Terminated

    Incorrect/Undeclared Excipients: Product contains undeclared FD&C Yellow No. 5 in the capsule shell.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Absorica Ld (Isotretinoin, Micronized)

2024 spending

$23K

Beneficiaries

n/a

14 claims

Per beneficiary

n/a

$42.31 per unit

View as table
YearSpending
2020$25,586
2021$81,264
2022$24,903
2023$62,964
2024$22,719

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 494 on PubMed

Sponsor: Sun Pharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.